NCT02201784

Brief Summary

The purpose of this study is to compare the effects of two intrathecally administered drugs:0.5% levobupivacaine and0.75%Ropivacaine in spinal anesthesia

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Dec 2012

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2012

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2014

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

July 24, 2014

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 28, 2014

Completed
6 months until next milestone

Results Posted

Study results publicly available

January 21, 2015

Completed
Last Updated

January 21, 2015

Status Verified

January 1, 2015

Enrollment Period

1.1 years

First QC Date

July 24, 2014

Results QC Date

January 14, 2015

Last Update Submit

January 14, 2015

Conditions

Keywords

Subarachnoid blockintrathecalspinal anesthesiaisobariclevobupivacaineropivacaine

Outcome Measures

Primary Outcomes (1)

  • Duration of Analgesia

    Defined as time for first analgesic request by the patient

    8 hours

Secondary Outcomes (5)

  • Onset of Sensory Block at T10

    30 minutes

  • Median Maximum Level of Sensory Blockade

    8 hours

  • Time to Maximum Cephalic Spread of Sensory Block

    8 hours

  • Onset of Motor Block to Bromage3

    8 hours

  • Duration of Motor Block

    8 hours

Other Outcomes (1)

  • Pulse Rate, Mean Arterial Pressure, SpO2

    8 hours

Study Arms (2)

Levobupivacaine 0.5%

ACTIVE COMPARATOR

intrathecal administration of 15 mg of Levobupivacaine 0.5%

Drug: Levobupivacaine

Ropivacaine 0.75%

ACTIVE COMPARATOR

intrathecal administration of 22.5 mg of Ropivacaine 0.75%

Drug: Ropivacaine

Interventions

Comparison of Equipotent doses

Also known as: Chirocaine
Levobupivacaine 0.5%

Comparison of equipotent doses

Also known as: Naropin
Ropivacaine 0.75%

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • American Society of Anesthesiologists (ASA) class I \& II patients of either sex
  • Age between 18-60 years

You may not qualify if:

  • Patient's refusal.
  • Patients who have contraindications to spinal anaesthesia / Local anaesthetic drugs.
  • Patients having h/o diabetes, neurological and musculoskeletal diseases.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Jawaharlal Nehru medical college, AMU

Aligarh, Uttar Pradesh, 202002, India

Location

MeSH Terms

Interventions

LevobupivacaineRopivacaine

Intervention Hierarchy (Ancestors)

BupivacaineAnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Limitations and Caveats

Exact baricity was not known as Specific gravity was not measured; Quality of anaesthesia was not assessed

Results Point of Contact

Title
Dr. Manazir Athar
Organization
Jawaharlal Nehru Medical College, AMU, Aligarh, India

Study Officials

  • Manazir Athar, M.D

    Jawaharlal Nehru Medical College, AMU,Aligarh, India

    PRINCIPAL INVESTIGATOR
  • Syed Moied Ahmed, PhD, M.D

    Jawaharlal Nehru Medical College, AMU, Aligarh, India

    STUDY DIRECTOR
  • Masood H Siddiqi, M.S

    Jawaharlal Nehru Medical College, AMU, Aligarh, India

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

July 24, 2014

First Posted

July 28, 2014

Study Start

December 1, 2012

Primary Completion

January 1, 2014

Study Completion

January 1, 2014

Last Updated

January 21, 2015

Results First Posted

January 21, 2015

Record last verified: 2015-01

Locations